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Treatment decision making in prostate 
cancer: Patients’ participation in  
complex decisions
Maarten Fischer, Adriaan Visser, Bert Voerman,  
Bert Garssen, George van Andel, Jozien Bensing
Op dat moment was ik 54. Dus dan heb je nog redelijke kans 
op genezing. Nou, zegt de uroloog, dat stadium zijn we ei-
genlijk al een beetje voorbij. Het is vrij agressief en ernstig. 
Ja, dat is toch wel even een klap. En dan moet je gaan over-
leggen wat er gaat gebeuren. Ja… opereren, bestralen, dat 
proces is vrij kort geweest.
(Respondent 112)
Patient Education and Counseling, 2006, 63, 308-313
Chapter 3




Objective: (1) To explore to what degree prostate cancer (PC) patients felt they had participated in treatment 
decision making (TDM). (2) To determine whether perceived roles during TDM were associated with medical and 
sociodemographic variables. (3) To examine to what extent satisfaction with TDM was related to perceived role or 
medical and sociodemographic variables.
Methods: Patients (n = 126) were recruited in hospitals and from the Dutch PC patient organization. The rela-
tionship between patients’ role and stage of disease, treatment modality, age, social status and education was 
determined, as well as patients’ satisfaction with TDM. 
Results: Most patients felt they had participated in TDM (autonomous 18%, collaborative 60%). Older patients 
and those with advanced disease more frequently reported not having been involved in decision making. Satisfac-
tion with TDM was related to age and role in TDM but not to stage of disease or treatment modality. Younger men 
were least content when they had not been involved in decision making. 
Conclusion: Patients’ level of participation and satisfaction with TDM appears to be related to medical and socio-
demographic variables. Practice implications: Satisfaction with TDM may be related to patients’ age and assumed 
role. It is recommended to take this into account when planning treatment for prostate cancer patients.
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Introduction
Prostate cancer is the most common malignancy in Dutch men, with approximately 7000 new cases diagnosed 
every year (Visser et al. 2002). The risk of developing the disease increases with age and is less common in men 
under 50. In the early stages of prostate cancer, few men will experience any physical symptoms. Therefore, early 
detection is often coincidental. The occurrence of physical symptoms (e.g. micturation problems and lower back 
pain) is associated with advanced stages of the disease. 
In case of a localized tumor, several curative treatment options exist, such as surgery (radical prostatectomy) or 
radiation therapy (by external beam or by radioactive seed implantation into the prostate). 
No curative treatment is currently available for patients with metastases. Treatment options for these patients 
consist of hormone therapy, which temporarily suppresses tumor growth, or chemotherapy (McMurtry & McMurtry 
2003). Radiation or surgery can relieve pain caused by bone metastases. Because the disease often develops 
slowly, ‘watchful waiting’ is an often chosen strategy for older men with prostate cancer, even in advanced stages 
(Van Andel et al. 1998).
Deciding on medical treatment for PC is complex for two reasons. First of all, there is still no worldwide consensus 
among specialists about which treatment should be applied in which disease condition (Van Andel 2003). For 
instance, surgery and radiation therapy have comparable effects on survival. Secondly, with regard to quality of 
life, each treatment option has high risks of side effects. With surgery, for instance, there is a high risk of erectile 
dysfunction and incontinence. Radiation will cause fewer side effects in the short run, but the occurrence of in-
continence and bladder problems increases with time after treatment (Shipley et al. 1994; Kornblith et al. 1994). 
Hormone treatment has a severe impact on libido, and therefore on the patient’s sex life (Catalona 1994). In older 
patients the costs of treatment on quality of life may even outweigh the expected benefits and lead to the decision 
not to initiate active treatment. The absence of one preferred treatment and the high risk of side effects make 
prostate cancer a disease suitable for shared decision making.
In TDM studies three types of decision making are usually distinguished (Davison & Degner 1997; Wong et al. 
2000): (a) active or autonomous decision making, indicating the patient is solely responsible for the decision; the 
physician’s preferences are not prominent and his role is that of a counselor; (b) collaborative or shared decision 
making, referring to the situation where both patient and physician share responsibility for the decision making; (c) 
a passive role of the patient implies that the patient is not involved in decision making. In this case the physician 
reviews the treatment options and makes the decision.
Recent research has shown that a large proportion of PC patients prefer to participate in TDM (Wong et al. 2000; 
Davison et al. 2004; Steginga & Occhipinti 2004; Gwede et al. 2005). However, little is known about patients’ 
actual participation in TDM. As it has been demonstrated that cancer patients’ preferred and assumed roles in 
TDM match in approximately 35–65% of the cases (Degner et al. 1997; Ramfelt et al. 2000; Gattellari et al. 2001; 
Keating et al. 2002; Ford et al. 2003), role preferences are not a reliable indication of patients’ level of participation. 
One recent study found that 94% of men with PC were involved (actively or collaboratively) in decision making 
(Davison & Goldenberg 2003). However, these men had taken part in a previous study designed to enhance their 
feeling of self-efficacy with regard to TDM.
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Limited research also exists about PC patients’ evaluation of the treatment planning consultation. A qualitative 
study showed that TDM consultations are often perceived as physician-led. Immediately after consultation pa-
tients were content with the paternalistic decision making style. However, acceptance of this one-sided decision 
making style decreased over time once patients were able to reflect on the complexity of their condition (Cohen 
& Britten 2003).
In order to shed new light on prostate cancer patients’ participation in TDM, the aim of this study is three-fold. 
First, to determine to what degree prostate cancer patients in retrospect feel they have been involved in TDM. 
Second, to explore the relationship between patients’ perceived roles in TDM and medical and sociodemographic 




This study was conducted as part of a longitudinal study on changes in quality of life and psychosocial problems 
among men with PC. Over a period of 10 months, with intervals of 4 and 6 months, respondents were asked to 
fill out three questionnaires (T1–T3), which they received by mail. Within the longitudinal study, all men with pros-
tate cancer were eligible, regardless of the stage of their disease and treatment. Exclusion criteria were: having 
or having had another type of cancer or serious illness, and inability to speak Dutch. Respondents were recruited 
in co-operation with the Dutch prostate cancer patients’ organization (SCP), in five hospitals, and during four 
educational meetings on prostate cancer. These educational meetings were organized by hospitals and offered 
information about prostate cancer and existing treatment options. The meetings were open to all patients with 
PC and partners.
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Questionnaire
The questionnaire covered sociodemographic, medical and psychosocial topics. Sociodemographic characteris-
tics included age, current relational status (‘Are you currently involved in an intimate relationship?’) and education. 
Education was classified as lower (primary school or lower vocational training), medium (secondary school or 
inter-mediate vocational training), or higher (higher vocational training or university). Medical aspects that were 
used in this study were: time since diagnosis (years), stage of disease (localized or metastatic disease) and type 
of treatment.
Psychological measures included coping style, quality of life and psychosocial distress (POMS) (Wald & Mellen-
bergh 1990). From the shortened version of the UCL we used three coping scales: active coping, avoidant coping 
and social support seeking (Schreurs et al. 1993). The European Organization for Research and Treatment of 
Cancer quality of life questionnaire (EORTC QLQ-C30), measures several dimensions of quality of life. In the pres-
ent study the ‘global quality of life’ subscale, consisting of two items was used (Aaronson et al. 1993). The Profile 
of Mood State (POMS) questionnaire includes five subscales: depression, anger, tension, fatigue and vigor (Wald 
& Mellenbergh 1990). All five subscales have been used in the present analyses. All used questionnaires showed 
sufficient reliability (Cronbach’s a UCL 0.70–0.87; POMS 0.90–0.92; ppmc EORTC 0.76).
With regard to TDM patients were first asked to indicate whether their doctor had discussed one or several 
treatment options, which may be an indication of physicians’ effort to involve patients in decision making. Next, 
respondents were asked to what degree they felt they had had the opportunity to decide about their treatment. 
For their answer patients had three options: ‘‘I had no say in the decision, the doctor made the decision’’ (passive), 
or ‘‘I have decided together with my doctor about my treatment’’ (collaborative), or ‘‘The doctor left the decision up 
to me’’ (autonomous). Finally, satisfaction was determined by asking respondents to evaluate (on a 5-point Likert 
scale, ranging from ‘‘very dissatisfied’’ to ‘‘very satisfied’’) the manner in which a decision about their treatment 
was reached. Except for the sociodemographic characteristics, which were only measured once (T1), all variables 
used in this study were obtained at T3.
Statistical analyses
Descriptive statistics were used to create an overview of respondents’ sociodemographic and medical character-
istics and role in TDM. Chi-square analyses were used to examine whether the patients’ role in TDM was related to 
medical (stage of disease, treatment modality) and sociodemo-graphic variables (age, education, relational status).
Non-parametric analyses of variance (Kruskal–Wallis) and post hoc contrast analyses with an overall significance 
level of 0.05 were used to test whether satisfaction scores varied with the role in TDM and the sociodemographic 
and medical variables mentioned above. Non-parametric ana-lyses of variance were also used to determine 
whether patients with an active, collaborative or passive role during TDM differed in coping style. Pearson correla-
tions were used to test the association between satisfaction with TDM and well being (quality of life and distress). 
An eventual relationship may reflect a general positive or negative attitude in life, which may act as a confounding 
factor in the relationship between perceived role and satisfaction with TDM.





The set of 3 questionnaires was completed by 187 of 261 (72%) respondents. Main reasons for drop out were 
worsening of medical condition and the wish not to be reminded of illness, or no longer motivated to complete 
questionnaires. In 33% of the cases patients gave no reason for dropping out. Time since diagnosis ranged 
from 0 to 11 years. To prevent a memory bias, patients who had been diagnosed longer than 3 years ago were 
further excluded from the analyses. Among the remaining 126 men, mean age was 67 years (range: 48–82) and 
on average PC diagnosis had occurred one and a half years ago (Table 1). Most respondents indicated they had 
a localized disease. Radical prostatectomy (RP) and hormone therapy (HT) were the most frequently reported 
treatment modalities, each reported by 29% of the respondents.
Patients’ participation in TDM
Most respondents (78%, n = 98), indicated that their doctor had reviewed more than one treatment option with 
them before a decision was made. With regard to the role in the decision making process, 60% (n = 75) stated 
they had decided in collaboration with their physician. A minority (18%, n = 22) indicated they had decided auton-
omously. Twenty-two percent (n = 28) answered they had not been involved in TDM.
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Table 1. Sociodemographic and medical characteristics (n = 126)
Men who reported to have had a passive role in TDM were in most cases (68%) presented with only one treatment 
option. Most respondents who had decided alone or in accordance with their physician remembered two or more 
treatment options were reviewed in the treatment consulta-tion (82% and 95%, respectively).
Medical and sociodemographic variables associated with patient participation in TDM
It was tested whether type of treatment was associated with patients’ involvement in decision making. Chi square 
analysis was performed on the 96 patients who had received a single treatment (i.e. radical prostatectomy, radi-
otherapy or hormone therapy).
N (%) Mean (SD)
Age 67.0 (7.9)
Education
  Lower 37 (29)
  Medium 42 (33)
  Higher 47 (37)
Time since diagnosis (years) 1.5 (1.1)
Stage of disease (metastases)
  No 75 (60)
  Yes 42 (33)
  Unknown to patients 8 (6)
Treatment
  Radical prostatectomy (RP) 37 (29)
  Hormone therapy (HT) 37 (29)
  Radiation therapy (RT) 22 (18)
  Intentionally curative and HT 21 (17)
  RP and RT 3 (2)
  No treatment/‘wait and see’ 6 (5)
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 Table 2. Patients’ roles across treatment, disease stage and age at time of diagnosis
Table 3. Patients’ satisfaction with TDM across perceived role (n = 125)
Although not reaching significance, there was a tendency towards a higher frequency of passive decision making for 
patients treated with hormone therapy (Table 2). Patients’ participation showed a significant association with stage 
of disease (Chi2 = 6.2, p < 0.05). Both patients with and without metastases had decided collaboratively in 59% 
of the cases. However, passive decision making was more frequent in patients with advanced disease (Table 2).
To test whether age at time of diagnosis had an influence patients’ role, the group of respondents was divided into 




  Surgery                (n = 37) 13 68 19
  Radiotherapy       (n = 22) 5 68 27
  Hormone therapy (n = 37) 32 54 14
Stage of disease b
  Localized  (n = 75) 18 59 23
  Metastatic (n = 42) 33 59 7
Age at time of diagnosis c
  65 and younger   (n = 61) 15 57 28
  Older than 65      (n = 65) 31 61 8
a Chi2 = 8.7, p = 0.07 
b Chi2 = 6.2, p < 0.05 (patients who could not tell the stage of their disease were left out of this analysis) 
c Chi2 = 10.9, p < 0.01
Role Quite dissatisfied
(%)
Neither satisfied  







Passive (a) (n = 28) 14 29 21 36 3.8   (4.0)
Collaborative (b) (n = 75) 4 4 24 68 4.6   (5.0)
Autonomous (c) (n = 22) 5 – 59 36 4.3   (4.0)
Kruskal–Wallis Chi2 = 14.8; p < 0.001. Post hoc comparison of satisfaction (a = 0.05): a < b
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The chi-square analysis revealed that role frequencies were not equal across age (Table 2). Younger respondents 
more often reported an autonomous role than older patients (Chi2 = 10.9, p < 0.01). No relationship was found 
between patients’ roles in TDM and education or marital status.
Satisfaction with TDM
Generally, satisfaction with the decision making process was very high. More than half (55%, n = 69) of the 
respondents were ‘‘very satisfied’’ and 29% (n = 37) were ‘‘quite satisfied’’. Nine percent (n = 11) were ‘‘neither 
dissatisfied nor satisfied’’ and only 6% (n = 8) were ‘‘quite dissatisfied’’.
Although the distribution of satisfaction scores was highly skewed, a relationship with patients’ perceived role 
during the process of decision making could be demonstrated (K–W Chi2 = 14.8, p < 0.01). Subsequent multiple 
comparison analyses revealed that men who had gone through passive decision making reported lower satisfac-
tion than those who had gone through collaborative decision making. Ratings from respondents who had decided 
autonomously did not differ significantly from those who had gone through collaborative or a passive decision 
making (Table 3).
Although hormone treatment and advanced stage of the disease were associated with rather high frequencies of 
passive decision making, satisfaction scores with TDM were not related to treatment modality (K–W Chi2 = 0.97, 
p > 0.1) or stage of disease (M–W U = 1483, p > 0.1). However, there was an association between age at time 
of diagnosis and satisfaction with TDM. Compared to the younger patients, older patients appeared to be more 
satisfied (M–W U = 1561, p < 0.05).
Since both patients’ perceived roles and their age at time of diagnosis appeared related to their satisfaction with 
TDM, a separate analysis for both age groups was conducted to detect a possible interaction effect between age 
and role on satisfaction scores. 
This analysis revealed that satisfaction scores of younger patients varied with the level of involvement in TDM (K–W 
Chi2 = 15.7, p < 0.001). Multiple comparison analyses revealed that patients who felt they had not been heard in 
TDM were less satisfied than patients who remembered to have decided collaboratively or autonomously (Table 4).











Passive (a)     (n = 9) 33 33 33 – 3.0 (3.0)
Collaborative (b) (n = 35) 9 3 29 60 4.4 (5.0)
Autonomous  (c)  (n = 17) – – 65 35 4.4 (4.0)
Kruskal–Wallis Chi2 = 15.7; p < 0.001. Post hoc comparison of satisfaction (α  = 0.05): a < b,c
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Table 5. Patients’ (age > 65) perceived role and satisfaction with TDM (n = 64)
For the older patient group satisfaction scores appeared to vary only slightly with their perceived role in TDM (K–W 
Chi2 = 5.9, p = 0.054). Post hoc comparison tests in de older patient group did not reach significance (Table 5). A 
classification of respondents on perceived role did not reveal any group differences in coping styles. Furthermore, 
all correlations between satisfaction and EORTC and POMS subscales were below r = 0.20. Satisfaction scores 










Passive (a)         (n = 19) 5 26 15 53 4.2 (5.0)
Collaborative (b) (n = 40) - 5 20 75 4.7 (5.0)
Autonomous (c) (n = 5) 20 – 40 40 4.0 (4.0)
Kruskal–Wallis Chi2 = 5.9; p = 0.054. Post hoc comparison of satisfaction (α = 0.05) ns
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Discussion and conclusion
Discussion
Since is it still undecided whether there is one superior treatment option for each stage of prostate cancer and 
risks of side effects with each treatment are high, there is much room for patient participation in medical decision 
making. Indeed, this study shows the degree of patient participation in TDM is high. Nearly 80% of the patients 
indicated they had selected their treatment by themselves or in collaboration with their physician. This level of 
participation is comparable to findings from previous research (Davison & Degner 1997; Davison & Goldenberg 
2003). The fact that participation in TDM was related to stage of disease (and treatment) may be explained by the 
fact that when metastases are discovered, few other options remain except for hormone treatment. As a result 
patients with advanced disease may be less often involved by physicians in the process of decision making. 
However, the fact that patients with advanced disease are not less satisfied with TDM may also be an indication of 
patients’ preference not to participate in TDM once their disease has become incurable (Benbassat et al. 1998).
In general, patients were very satisfied with the process of decision making, especially those who indicated to 
have decided in close collaboration with their doctor. Patients in a passive role were least satisfied. Satisfaction 
with TDM was also related to the age at which patients were diagnosed. Patients diagnosed at older age were 
more satisfied with TDM than men who were younger at time of diagnosis.
Moreover, the age at which patients had been diagnosed and the perceived role showed an interaction effect on 
satisfaction with TDM. Younger patients turned out to be less satisfied with a passive role compared to patients 
who had decided autonomously or collaboratively. Whereas none of the younger patients who had gone through 
passive decision making were ‘very satisfied’ with TDM, more than half of the older patients with a passive role 
were ‘very satisfied’ with the decision making process. The association between patients’ preference for partici-
pation in TDM and younger age has been found in several studies (Say et al. 2006). One possible explanation for 
this finding is a socio-cultural change in the patient–physician interaction. A physician-centered communication 
style (with the doctor being solely responsible for the medical decisions) in cancer management has long been 
undisputed e.g. (Lerner 2004). Nowadays, patients tend to become more knowledgeable with medical information 
readily accessible. It has been demonstrated that patients who feel well informed show a greater preference for 
involvement in TDM (Davison & Degner 1997).
Our empirical findings have some limitations and consequently leave questions to be answered in future research. 
First of all, our study sample is small and heterogeneous. Therefore one should be cautious in interpreting these 
findings. Second, we have limited insight in the factors that influence a decision making style during consultation. 
Our findings suggest that patients’ coping style does not influence their assumed role during TDM. Patients with 
an active role are not characterized by a high problem-focused coping style, as one might expect. Future research 
needs to further focus on factors (patient and physician factors) that determine the role that patients attain during 
TDM. For example, a passive role in decision making may be a consequence of patients’ low internal locus of 
control and a strong belief in the abilities of his physician (Steginga & Occhipinti 2004). On the other hand, it might 
also be a reflection of a physician’s paternalistic communication style (Cohen & Britten 2003).
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Third, patients’ conceptual definition of ‘deciding together with the doctor about medical treatment’ needs to be 
established. Our results did show that most men with a collaborative or autonomous role had been presented 
with two or more treatment options. However, it is not clear to what degree patients’ treatment preferences were 
discussed in collaborative decision making. After all, shared decision making involves more than the patient’s 
approval once the doctor has presented a treatment proposal. In other words, what aspects in communication do 
patients consider a prerequisite for ‘shared decision making’?
Conclusion
In sum, most Dutch PC patients feel they have been involved in the process of deciding about treatment. Older 
patients and patients with metastases more frequently feel they have had a passive role in TDM compared with 
younger patients and those without metastases. On the whole, a collaborative role is associated with higher pa-
tient satisfaction about TDM. This seems particularly true for younger patients.
Practice implications
Notwithstanding the limitations of our study, the high satisfaction with TDM of patients who had decided in collab-
oration with their doctor supports our plea for shared decision making in prostate cancer. Our data suggest that 
this may be particularly important for patients diagnosed at younger age. To date, the number of treatment options 
for patients with advanced disease is limited. However, it is important to note that this fact in itself does not restrict 
the possibility for patients to participate in TDM. 
Educating patients (and partners) about the benefits and drawbacks of hormone treatment together with the 
patient and leaving room for negotiation about whether and when to initiate treatment (for instance dependent 
on patients’ sexual activity), may enhance a sense of control and perception of participation in decision making.
One final word of caution may be in order. Patient-centeredness in medicine does not necessarily imply shared de-
cision making. Medical decision making for PC is difficult. Sometimes for professionals, often for patients (Gwede 
et al. 2005; Steginga et al. 2002). It is important to keep in mind that the individual patient may or may not feel 
comfortable with the responsibility of choosing between the available treatment options and too much encourage-
ment towards active involvement in TDM may lead to unwanted control (Woolf et al. 2005). Where possible, we 
would like to encourage clinicians to assess the degree to which patients want to be involved in TDM. Enabling 
patients to take on their preferred role in TDM may reduce patients’ anxiety (Gattellari et al. 2001) and increase 
satisfaction with the treatment choice (Keating et al. 2002).
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